Kangmei Pharmaceutical Co., Ltd. (SHA:600518)
China · Delayed Price · Currency is CNY 1.710
-0.020 (-1.16%)
Apr 30, 2026, 3:00 PM CST
Kangmei Pharmaceutical Revenue
In the year 2025, Kangmei Pharmaceutical had annual revenue of 5.25B CNY with 1.22% growth. Kangmei Pharmaceutical had revenue of 1.29B in the quarter ending December 31, 2025, a decrease of -1.75%.
Revenue
5.25B
Revenue Growth
+1.22%
P/S Ratio
4.50
Revenue / Employee
1.24M
Employees
4,233
Market Cap
23.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.25B | 63.08M | 1.22% |
| Dec 31, 2024 | 5.19B | 315.12M | 6.47% |
| Dec 31, 2023 | 4.87B | 693.87M | 16.60% |
| Dec 31, 2022 | 4.18B | 27.63M | 0.67% |
| Dec 31, 2021 | 4.15B | -1.26B | -23.27% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Livzon Pharmaceutical Group | 11.71B |
| Apeloa Pharmaceutical Co.,Ltd | 9.50B |
| Zhejiang Huahai Pharmaceutical | 8.71B |
| Tasly Pharmaceutical Group | 8.35B |
| Jiangsu Nhwa Pharmaceutical Co., LTD | 6.01B |
| Hubei Jumpcan Pharmaceutical | 5.90B |
| Chengdu Kanghong Pharmaceutical Group | 4.43B |
| Betta Pharmaceuticals | 3.73B |